Current Research Studies at TUCC
• Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance – Active, recruiting new patients A study for men diagnosed with early stage (localized) prostate cancer and are undergoing active surveillance (being observed over time to see if your prostate cancer changes). The purpose of this study is to see if enzalutamide, an approved product for treating prostate cancer in advanced stages, can delay the progression of early stage prostate cancer. • Niraparib for the treatment of Advanced Prostate Cancer – Active, recruiting new patients A Phase 2 efficacy and safety study of Niraparib in men with metastatic castration- resistant prostate cancer and DNA-repair anomalies. The main purpose of this study is to see if Niraparib is useful to treat men with advanced prostate cancer. The safety of niraparib will also be studied. • Phase III Prostate Cancer Clinical Trial – Active, recruiting new patients The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease. • A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer – Active, recruiting new patients The purpose of this study is to determine the benefit and safety of relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (<=50 ng/dL [1.7 nmol/L] in patients with androgen-sensitive advanced prostate cancer. • An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies – Active, recruiting new patients The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies. • Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC With Deoxyribonucleic Acid (DNA) Damage Repair Deficiencies (DDR) – Active, recruiting new patients This study compares rPFS in men with DDR deficiency(ies) mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide. • A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT – Active, recruiting new patients This is a randomized, multicenter, two-arm, double-blind, placebo-controlled study of Qapzola in patients with low- to intermediate-risk NMIBC, assessed according to the 2016 American Urology Association (AUA) Guidelines. Specifically, only patients with the following low-to intermediate risk tumor characteristics will be included in the study.